| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Mainstream news |
| Population | Women |
| Source | ARY News (Reuters) |
| URL | arynews.tv/us-examines-testosterone-therapy-for-women (opens in a new tab) |
Specific Claim Evaluated
Evidence supports testosterone only for postmenopausal women with hypoactive sexual desire disorder, data are insufficient for mood, cognition or well-being, and oral testosterone is not recommended because of cholesterol effects.
Primary Research Supporting or Contradicting the Claim
The consensus statement supports testosterone only for postmenopausal hypoactive sexual desire disorder and advises against oral formulations because of adverse lipid effects (Davis et al., 2019; Islam et al., 2019).
Corrected Evidence-Based Interpretation
The report is correct.
Rationale for Grade
The article presents differing views from the workshop, states the regulatory history and reports the evidence base accurately.
References
- Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD." - Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. PMID
Supporting excerpt: "Testosterone is effective for postmenopausal women with low sexual desire causing distress"